NTI 1.45% 6.8¢ neurotech international limited

Ann: Scientific Advisory Board, page-2

  1. 4,246 Posts.
    lightbulb Created with Sketch. 1161
    Neurotech forms Scientific Advisory Board

    Perth, Australia & Malta – 20 December 2016 – Developer of quality medical solutions in the neuroscience space, Neurotech International Limited (ASX: NTI), has finalised the appointment of its Scientific Advisory Board (SAB).
    The SAB will act as strategic counsel to Neurotech, guiding company management as it enters the market with its Mente Autism device, in addition to the development of other devices targeting various neurological disorders.
    The SAB is comprised of:

    • Prof Paolo Cavallari – Professor of Human Physiology, University of Milan
    • Prof Denis Azzopardi – Professor of Neonatal Medicine, Kings College, UK
    • Dr David S Cantor – Former President of the EEG and Clinical Neuroscience Society, USA
    • Dr Anton Grech – Senior Research Fellow, Bedfordshire Centre for Mental Health Research

    Full biographies for each member of the SAB are available below.
    Neurotech’s Founder and Chief Scientific Officer Dr Adrian Attard Trevisan will act as moderator/chair to the SAB, with Dr Marco Rotonda, the company’s Senior Neuroscientist, filling the role of board secretary.

    “As a company we are very excited to have the input of such a high calibre group of individuals in the neuroscience space,” said Dr Attard Trevisan.
    “To attract such talent onto our Scientific Advisory Board is excellent validation of Neurotech, its technology and direction.”

    The SAB will convene once per quarter with each member requiring re-election every calendar year. Additional members may be added in the future, with a view to having exposure within other geographies.
    The key deliverable expected of the SAB is a ‘Company Vision Document’, which will be delivered to the Board of Neurotech in the final quarter of each calendar year.


    “We have assembled a team for our Scientific Advisory Board with wide-ranging, high quality experience relevant to Neurotech’s business activities and objectives, and reflective of the jurisdictions the company is targeting in the immediate to medium term,” Neurotech’s CEO Wolfgang Storf said.

    “The aim and functions of the Scientific Advisory Board are extremely important to Neurotech, and we expect it will act as a key decision maker for the company’s scientific and technological vision.”


    Biographies

    Prof Paolo Cavallari, MD PhD
    Paolo Cavallari is Professor of Human Physiology (2001) at the Medical School of the Università degli
    Studi in Milan, Italy. Prof Cavallari received his MD (magna cum laude) from the University of Milan in
    1982, a Diplome d’Etudes Appofondies in Neurophysiology from the Pierre et Marie Curie University
    of Paris in 1984, a Doctorat de l'Université from the same university in 1988 and a PhD in Neurological
    Science from the University of Milan in 1990. He received fellowships from the European Neuroscience
    Association (1984) and from the IBRO-Wenner-Gren Foundation (1986). He had non-tenure track
    positions from the INSERM (France, 1985) and the Göteborg University (Sweden, 1987), and tenured
    as Associate Professor of Human Physiology in 1992 at the Università degli Studi of L'Aquila (1992-
    1997), and at Università degli Studi (1997-2001).

    Prof Denis Azzopardi, MD PhD
    Denis Azzopardi is Professor of Neonatal Medicine at Kings College, London. For many years he has
    been involved in clinical research in the investigation, assessment and treatment of neonatal
    encephalopathy, having developed and implemented the first proven therapy to reduce severe brain
    damage and improve survival after birth asphyxia. In developing this therapy, magnetic resonance
    spectroscopy was used to demonstrate birth asphyxia in newborn infants leads to delayed brain injury,
    and that there is a ‘lucid period’ when neuroprotective treatments could potentially be applied. This
    in turn led to the now standard practice of cooling infants below normal body temperature as the
    standard practice for those suffering from oxygen deprivation during birth in the United Kingdom (UK).
    Estimates suggest that this treatment has saved the UK over £100 million in the costs of caring for
    people affected by birth asphyxia, and is now implemented across the world.

    Dr David S Cantor, PhD
    Dr David Cantor received his Bachelor’s Degree with Distinction in Psychology from the University of
    Connecticut. His honours work was in the field of neurophysiological correlates of cross modal
    integration processes in attention deficit disorders. He received his Masters and Doctorate in
    psychology at the State University of New York (Stony Brook), where his thesis was focussed on
    quantitative EEG correlates of autism. He most recently received his Postdoctoral Masters of Science
    in Psychopharmacology from Fairleigh University.
    Dr Cantor is a Fellow with the American College of Forensic Examiners, National Academy of
    Neuropsychology, and the Academy of Learning and Developmental Disorders. He is also Former
    President of the EEG and Clinical Neuroscience Society and has also been accepted for special
    fellowships including Congressional Fellow of the American Psychological Association and the State of
    New York Intercampus Fellow in the area of brain research.

    Dr Anton Grech, MD PhD
    Dr Anton Grech graduated as Doctor of Medicine from the University of Malta in 1992. He became a
    Member of the Royal College of Psychiatrists, UK, in 1997 and a Fellow of the same college in 2011. In
    1999 he obtained an M.Sc. in Psychiatry from King’s College, University of London. He trained and
    worked at the Maudsley Hospital in London, between 1994 and 1998. During 1998 he was also a
    Clinical-Academic Lecturer in the Department of Psychiatry, Institute of Psychiatry, King’s College,
    University of London.

    Dr Grech returned to Malta in 1999, where he was Senior Registrar in Psychiatry with the National
    Health Service of Malta until 2003, when he was appointed Consultant Psychiatrist with a special
    interest in Addictions and Neuropsychiatry. In 2000 he was appointed Lecturer in the Department of
    Psychiatry of the Faculty of Medicine and Surgery at the University of Malta, and in 2008 he was
    appointed as Senior Lecturer within the same department. In 2011 he was appointed as Senior PAGE | 3
    Research Fellow in the Bedfordshire Centre for Mental Health Research in association with the
    University of Cambridge, United Kingdom. In 2011 he was also appointed as Clinical Chairman of the
    Department of Psychiatry in the Ministry of Health, Malta.

    Dr Grech’s work has been published in international psychiatric journals, and he has presented and
    chaired in various international psychiatric conferences. In 2008 he was chosen as one of the 30
    European Scientists to be featured in the book ‘Portraits of Science; Scientists of Tomorrow’, published
    by the European Federation of Pharmaceutical Industries and Associations, to commemorate its 30th
    anniversary.
    Last edited by stotes: 20/12/16
 
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
(20min delay)
Last
6.8¢
Change
-0.001(1.45%)
Mkt cap ! $69.19M
Open High Low Value Volume
6.9¢ 6.9¢ 6.8¢ $23.3K 341.7K

Buyers (Bids)

No. Vol. Price($)
1 249524 6.8¢
 

Sellers (Offers)

Price($) Vol. No.
6.9¢ 11111 1
View Market Depth
Last trade - 15.43pm 04/09/2024 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.